Doctor Essra Ridha
Bristol-Myers Squibb Pharmaceuticals Limited , London (United Kingdom of Great Britain & Northern Ireland)
Are your atrial fibrillation (AF) patients protected from ischaemic stroke? Clinical characteristics of AF patients eligible for stroke prevention but remaining untreated in UK clinical practice
Event: ESC Congress 2016
Topic: Atrial fibrillation (AF)
Session: Anticoagulation in atrial fibrillation II
Is Aspirin monotherapy effective for stroke prevention in the real world? A UK cohort study evaluating the incidence of stroke in the absence of anticoagulation in atrial fibrillation (AF)
Event: ESC Congress 2016
Topic: Atrial fibrillation (AF)
Session: Anticoagulation in atrial fibrillation II
Aspirin, not without bleeding risk in the real world: results of a UK cohort study evaluating the use of antiplatelet therapy for stroke prevention in atrial fibrillation (AF)
Event: ESC Congress 2016
Topic: Atrial fibrillation (AF)
Session: Anticoagulation in atrial fibrillation III
ESC 365 is supported by
